Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: Recent achievements and perspectives

Drug Discovery Today

Volumn 15, Issue 23-24, 2010, Pages 1070-1078

  Navarro, Maribel ^a   Gabbiani, Chiara ^b   Messori, Luigi ^b   Gambino, Dinorah ^c  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

(2,2':6'2'' TERPYRIDINE)PLATINUM; 5 NITROFURYL DERIVED THIOSEMICARBAZONE; AMODIAQUINE; ANTIMONY; ARTEMETHER; ARTESUNATE; AUROTHIOMALATE; BENFLUMETOL; BENZNIDAZOLE; CHLOROQUINE; CISPLATIN; COTRIFAZID; DOXYCYCLINE; FERROQUINE; GOLD CHLOROQUINE; HYDROXYCHLOROQUINE; IRIDIUM CHLOROQUINE; MEFLOQUINE; MILTEFOSINE; NIFURTIMOX; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; PYRITHIONE; QUININE; RUTHENIUM CLOROQUINE; SULFADOXINE; TRIETHYLPHOSPHINE GOLD; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC SULFATE;

AFRICAN TRYPANOSOMIASIS; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CHAGAS DISEASE; CHEMOTHERAPY; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; DNA BINDING; DRUG DNA INTERACTION; DRUG SYNTHESIS; GENOMICS; HUMAN; LEISHMANIASIS; MALARIA; MALARIA FALCIPARUM; MOLECULAR BIOLOGY; NONHUMAN; PLASMODIUM BERGHEI INFECTION; PUBLIC HEALTH PROBLEM; REVIEW; SKIN LEISHMANIASIS; TRYPANOSOMIASIS;

ANTIMALARIALS; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIASIS; MALARIA; METALS; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS;

EID: 78649635805     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.10.005     Document Type: Review

References (52)

1. Bruijnincx P.C., Sadler P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol. 2008, 12:197-206.
2. Zhang C.X., Lippard S.J. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. 2003, 7:481.
3. Dyson P.J., Sava G. Metal-based antitumour drugs in the post genomic era. Dalton Trans. 2006, 16:1929-1933.
4. Sánchez-Delgado R.A., Anzellotti A. Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiais, malaria and leishmaniasis. Mini Rev. Med. Chem. 2004, 4:23-30.
5. Sánchez-Delgado R.A., et al. Metal complexes as chemotherapeutic agents against tropical diseases: malaria, trypanosomiasis, and leishmaniasis. Metal ions in biological systems. Metal Ions and Their Complexes in Medication 2004, vol. 41:379-419. Marcel Dekker.
6. Mital A. Recent advances in antimalarial compounds and their patents. Curr. Med. Chem. 2007, 14:759.
7. Sharma V. Therapeutic drugs for targeting chloroquine resistance in malaria. Mini Rev. Med. Chem. 2005, 5:337-351.
8. Navarro M. Gold complexes as potential anti-parasitic agents. Coord. Chem. Rev. 2009, 253:1619-1626.
9. Navarro M., et al. Synthesis, characterization and antimalarial activity of new iridium-chloroquine complexes. Polyhedron 2007, 12:2420-2424.
10. Rajapakse C.S.K., et al. Synthesis, characterization and in vitro antimalarial and antitumor activity of new ruthenium (II) complexes of chloroquine. Inorg. Chem. 2009, 48:1122-1131.
11. 2. J. Biol. Inorg. Chem. 2008, 13:703.
12. Martínez A., et al. The antimalarial activity of Ru-chloroquine complexes against resistant Plasmodium falciparum is related to lipophilicity, basicity, and heme aggregation inhibition ability near water/n-octanol interfaces. J. Biol. Inorg. Chem. 2009, 14:863.
13. Biot C., et al. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. J. Med. Chem. 1997, 40:3715-3718.
14. Dive D., Biot C. Ferrocene conjugates of chloroquine and other antimalarials: the development of ferroquine, a new antimalarial. ChemMedChem 2008, 3:383-391.
15. Sannella A.R., et al. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett. 2008, 582:844-847.
16. Messori L., et al. Outstanding plasmodicidal properties within a small panel of metallic compounds: hints for the development of new metal-based antimalarials. J. Inorg. Biochem. 2009, 103:310-312.
17. Andricopulo A.D., et al. Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. Bioorg. Med. Chem. Lett. 2006, 16:2283-2292.
18. Rosenthal P.J. Cysteine proteases of malaria parasites. Int. J. Parasitol. 2004, 34:1489-1499.
19. Hotez P.J., et al. Control of neglected tropical diseases. N. Engl. J. Med. 2007, 357:1018-1027.
20. Delespaux V., de Koning H.P. Drugs and drug resistance in African trypanosomiasis. Drug Resist. Updat. 2007, 10:30-50.
21. Ribeiro I., et al. New improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl. Trop. Dis. 2009, 3:e484.
22. Urbina J. New chemotherapeutic approaches for the treatment of Chagas disease. Exp. Opin. Ther. Patents 2003, 13:661-669.
23. Maya J.D., et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp. Biochem. Physiol. A 2007, 146:601-620.
24. Croft S.L., et al. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 2005, 21:508-512.
25. Cavalli A., Bolognesi M.L. Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania. J. Med. Chem. 2009, 52:7339-7359.
26. Moreira D.R., et al. Approaches for the development of new anti-Trypanosoma cruzi agents. Curr. Drug Targets 2009, 10:212-231.
27. Fricker S.P., et al. Metal compounds for the treatment of parasitic diseases. J. Inorg. Biochem. 2008, 102:1839-1845.
28. Otero L., et al. Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes: DNA and redox metabolism as potential therapeutic targets. J. Med. Chem. 2006, 49:3322-3331.
29. Vieites M., et al. Platinum(II) metal complexes as potential anti-Trypanosoma cruzi agents. J. Inorg. Biochem. 2008, 102:1033-1043.
30. Vieites M., et al. Platinum-based complexes of bioactive 3-(5-nitrofuryl)acroleine thiosemicarbazones showing anti-Trypanosoma cruzi activity. J. Inorg. Biochem. 2009, 103:411-418.
31. Vieites M., et al. Potent in vitro anti-Trypanosoma cruzi activity of pyridine-2-thiol N-oxide metal complexes having inhibitory effect on parasite-specific fumarate reductase. J. Biol. Inorg. Chem. 2008, 13:723-735.
32. Vieites M., et al. Synthesis and characterization of a pyridine-2-thiol N-oxide gold(I) complex with potent antiproliferative effect against Trypanosoma cruzi and Leishmania sp. Insight into its mechanism of action. J. Inorg. Biochem. 2009, 103:1300-1306.
33. Kinnamon K.E., et al. Activity of antitumor drugs against African trypanosomes. Antimicrob. Agents Chemother. 1979, 15:157-160.
34. Benítez J., et al. A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: a potential anti-protozoa and anti tumor agent. J. Inorg. Biochem. 2009, 103:1386-1394.
35. Benítez J., et al. Design of vanadium mixed-ligand complexes as potential anti-protozoa agents. J. Inorg. Biochem. 2009, 103:609-616.
36. Blum J., et al. Treatment of cutaneous leishmaniasis among travellers. J. Antimicrob. Chemother. 2004, 53:158-166.
37. Le Pape P. Development of new antileishmanial drugs-current knowledge and future prospects. J. Enzyme Inhib. Med. Chem. 2008, 23:708-718.
38. Mishra J., et al. Chemotherapy of leishmaniasis: past, present and future. Curr. Med. Chem. 2007, 14:1153-1169.
39. Minodier P., Parola P. Cutaneous leishmaniasis treatment. Travel Med. Infect. Dis. 2007, 5:150-158.
40. Lowe G., et al. Cytotoxicity of (2,2':6,2"-terpyridine) platinum (II) complexes to Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Med. Chem. 1999, 42:999-1006.
41. 3. DNA interaction studies and biological activity against Leishmania (L) mexicana. J. Inorg. Biochem. 2007, 101:111-116.
42. Krauth-Siegel R.L., et al. Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew. Chem. Int. Ed. Engl. 2005, 44:690-715.
43. Krauth-Siegel R.L., Comini M.A. Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochim. Biophys. Acta 2008, 1780:1236-1248.
44. Baiocco P., et al. Molecular basis of antimony treatment in leishmaniasis. J. Med. Chem. 2009, 52:2603-2612.
45. Nickel C., et al. Thioredoxin networks in the malarial parasite Plasmodium falciparum. Antioxid. Redox Signal. 2006, 8:1227-1239.
46. Hickey J.L., et al. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J. Am. Chem. Soc. 2008, 130:12570-12571.
47. Berners-Price S.J., Filipovska A. The design of gold-based, mitochondria-targeted chemotherapeutics. Aus. J. Chem. 2008, 61:661-668.
48. Barnard P.J., Berners-Price S.J. Targeting the mitochondrial cell death pathway with gold compounds. Coord. Chem. Rev. 2007, 251:1889-1902.
49. Barnard P.J., et al. Mitochondrial permeability transition induced by dinuclear gold(I)-carbene complexes: potential new antimitochondrial antitumour agents. J. Inorg. Biochem. 2004, 98:1642-1647.
50. Sajid M., McKerrow J.H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 2002, 120:1-21.
51. McKerrow J.H., et al. Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg. Med. Chem. 1999, 7:639-644.
52. Mottram J.C., et al. Cysteine peptidases as virulence factors of Leishmania. Curr. Opin. Microbiol. 2004, 7:375-381.